Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on May 17, 2004

Hypertension. 2004
Published online before print May 17, 2004, doi: 10.1161/01.HYP.0000130484.20501.df
A more recent version of this article appeared on July 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/1/6    most recent
01.HYP.0000130484.20501.dfv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jialal, I.
Right arrow Articles by Venugopal, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jialal, I.
Right arrow Articles by Venugopal, S. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Risk Factors
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology

Submitted on February 16, 2004
Revised on March 5, 2004

C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?

Ishwarlal Jialal*; Sridevi Devaraj; and Senthil K. Venugopal

From the Laboratory for Atherosclerosis and Metabolic Research, UC Davis Medical Center, Sacramento, Calif.

* To whom correspondence should be addressed. E-mail: ishwarlal.jialal{at}ucdmc.ucdavis.edu.

Abstract--Inflammation appears to be pivotal in all phases of atherosclerosis from the fatty streak lesion to acute coronary syndromes. An important downstream marker of inflammation is C-reactive protein (CRP). Numerous studies have shown that CRP levels predict cardiovascular disease in apparently healthy individuals. This has resulted in a position statement recommending cutoff levels of CRP <1.0, 1.0 to 3.0, and >3.0 mg/L equating to low, average, and high risk for subsequent cardiovascular disease. More interestingly, much in vitro data have now emerged in support of a role for CRP in atherogenesis. To date, studies largely in endothelial cells, but also in monocyte-macrophages and vascular smooth muscle cells, support a role for CRP in atherogenesis. The proinflammatory, proatherogenic effects of CRP that have been documented in endothelial cells include the following: decreased nitric oxide and prostacyclin and increased endothelin-1, cell adhesion molecules, monocyte chemoattractant protein-1 and interleukin-8, and increased plasminogen activator inhibitor-1. In monocyte-macrophages, CRP induces tissue factor secretion, increases reactive oxygen species and proinflammatory cytokine release, promotes monocyte chemotaxis and adhesion, and increases oxidized low-density lipoprotein uptake. Also, CRP has been shown in vascular smooth muscle cells to increase inducible nitric oxide production, increase NF{kappa}b and mitogen-activated protein kinase activities, and, most importantly, upregulate angiotensin type-1 receptor resulting in increased reactive oxygen species and vascular smooth muscle cell proliferation. Future studies should be directed at delineating the molecular mechanisms for these important in vitro observations. Also, studies should be directed at confirming these findings in animal models and other systems as proof of concept. In conclusion, CRP is a risk marker for cardiovascular disease and, based on future studies, could emerge as a mediator in atherogenesis.


Key words: endothelium • macrophages • atherosclerosis




This article has been cited by other articles:


Home page
CVIHome page
J. J. M. Bouwman, R. J. A. Diepersloot, and F. L. J. Visseren
Intracellular Infections Enhance Interleukin-6 and Plasminogen Activator Inhibitor 1 Production by Cocultivated Human Adipocytes and THP-1 Monocytes
Clin. Vaccine Immunol., August 1, 2009; 16(8): 1222 - 1227.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. U. Eisenhardt, J. Habersberger, A. Murphy, Y.-C. Chen, K. J. Woollard, N. Bassler, H. Qian, C. von zur Muhlen, C. E. Hagemeyer, I. Ahrens, et al.
Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques
Circ. Res., July 17, 2009; 105(2): 128 - 137.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
F. Montecucco, F. Burger, G. Pelli, N. K. Poku, C. Berlier, S. Steffens, and F. Mach
Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes
Rheumatology, March 1, 2009; 48(3): 233 - 242.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. D. Hingorani, T. Shah, J. P. Casas, S. E. Humphries, and P. J. Talmud
C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Clin. Chem., February 1, 2009; 55(2): 239 - 255.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
F. Montecucco, S. Steffens, F. Burger, G. Pelli, C. Monaco, and F. Mach
C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes
J. Leukoc. Biol., October 1, 2008; 84(4): 1109 - 1119.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. M Ridker
The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP?
Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1222 - 1224.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
U. Singh, M. R. Dasu, P. G. Yancey, A. Afify, S. Devaraj, and I. Jialal
Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats
J. Lipid Res., May 1, 2008; 49(5): 1015 - 1023.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. L. Marcovecchio, C. Giannini, B. Widmer, R. N. Dalton, S. Martinotti, F. Chiarelli, and D. B. Dunger
C-Reactive Protein in Relation to the Development of Microalbuminuria in Type 1 Diabetes: The Oxford Regional Prospective Study
Diabetes Care, May 1, 2008; 31(5): 974 - 976.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
S. H. Rahman, J. Evans, G. J. Toogood, P. A. Lodge, and K. R. Prasad
Prognostic Utility of Postoperative C-reactive Protein for Posthepatectomy Liver Failure
Arch Surg, March 1, 2008; 143(3): 247 - 253.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Nishikawa, K. Hagihara, S. Serada, T. Isobe, A. Matsumura, J. Song, T. Tanaka, I. Kawase, T. Naka, and K. Yoshizaki
Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1{alpha} Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression
J. Immunol., March 1, 2008; 180(5): 3492 - 3501.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
X. Wang, D. Liao, U. Bharadwaj, M. Li, Q. Yao, and C. Chen
C-Reactive Protein Inhibits Cholesterol Efflux From Human Macrophage-Derived Foam Cells
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 519 - 526.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. Xing, F. G. Hage, Y.-F. Chen, M. A. McCrory, W. Feng, G. A. Skibinski, E. Majid-Hassan, S. Oparil, and A. J. Szalai
Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc{gamma}RI)-Dependent
Am. J. Pathol., January 1, 2008; 172(1): 22 - 30.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. N. Patel, C. A. King, S. R. Bailey, J. W. Holt, K. Venkatachalam, A. Agrawal, A. J. Valente, and B. Chandrasekar
Interleukin-17 Stimulates C-reactive Protein Expression in Hepatocytes and Smooth Muscle Cells via p38 MAPK and ERK1/2-dependent NF-{kappa}B and C/EBPbeta Activation
J. Biol. Chem., September 14, 2007; 282(37): 27229 - 27238.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Kovacs, P. Tornvall, R. Nilsson, J. Tegner, A. Hamsten, and J. Bjorkegren
Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia
PNAS, August 21, 2007; 104(34): 13768 - 13773.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
Y. S. Choi, J. Hur, and S. Jeong
{beta}-Catenin binds to the downstream region and regulates the expression C-reactive protein gene
Nucleic Acids Res., August 17, 2007; (2007) gkm547v1.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev., August 1, 2007; 28(5): 463 - 491.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. Moran, M. Noakes, P. M. Clifton, G. A. Wittert, D. P. Belobrajdic, and R. J. Norman
C-Reactive Protein before and after Weight Loss in Overweight Women with and without Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2944 - 2951.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. K. Bello, D. de Zeeuw, M. E. Nahas, A. H. Brantsma, S. J. L. Bakker, P. E. de Jong, and R. T. Gansevoort
Impact of weight change on albuminuria in the general population
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1619 - 1627.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Ridker
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus
J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Schwartz, S. Osborne-Lawrence, L. Hahner, L. L. Gibson, A. K. Gormley, W. Vongpatanasin, W. Zhu, R. A. Word, D. Seetharam, S. Black, et al.
C-Reactive Protein Downregulates Endothelial NO Synthase and Attenuates Reendothelialization In Vivo in Mice
Circ. Res., May 25, 2007; 100(10): 1452 - 1459.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters
Systemic Effects of Smoking
Chest, May 1, 2007; 131(5): 1557 - 1566.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. J. Bisoendial, J. J. P. Kastelein, S. L. M. Peters, J. H. M. Levels, R. Birjmohun, J. I. Rotmans, D. Hartman, J. C. M. Meijers, M. Levi, and E. S. G. Stroes
Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects
J. Lipid Res., April 1, 2007; 48(4): 952 - 960.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. R. Dasu, S. Devaraj, T. W. Du Clos, and I. Jialal
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells
J. Lipid Res., March 1, 2007; 48(3): 509 - 512.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S.-R. Ji, Y. Wu, L. Zhu, L. A. Potempa, F.-L. Sheng, W. Lu, and J. Zhao
Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm
FASEB J, January 1, 2007; 21(1): 284 - 294.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
L. A. Lange, C. S. Carlson, L. A. Hindorff, E. M. Lange, J. Walston, J. P. Durda, M. Cushman, J. C. Bis, D. Zeng, D. Lin, et al.
Association of Polymorphisms in the CRP Gene With Circulating C-Reactive Protein Levels and Cardiovascular Events
JAMA, December 13, 2006; 296(22): 2703 - 2711.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Devaraj, E. Chan, and I. Jialal
Direct Demonstration of an Antiinflammatory Effect of Simvastatin in Subjects with the Metabolic Syndrome
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4489 - 4496.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Fujii, S.-H. Li, P. E. Szmitko, P. W.M. Fedak, and S. Verma
C-Reactive Protein Alters Antioxidant Defenses and Promotes Apoptosis in Endothelial Progenitor Cells
Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2476 - 2482.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. de Voogd, R. C. W. Wolfs, N. M. Jansonius, J. C. M. Witteman, A. Hofman, and P. T. V. M. de Jong
Atherosclerosis, C-reactive protein, and risk for open-angle glaucoma: the rotterdam study.
Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3772 - 3776.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Devaraj, B. Davis, S. I. Simon, and I. Jialal
CRP promotes monocyte-endothelial cell adhesion via Fc{gamma} receptors in human aortic endothelial cells under static and shear flow conditions
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1170 - H1176.
[Abstract] [Full Text] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
T. Dziedzic
Systemic inflammatory markers and risk of dementia.
American Journal of Alzheimer's Disease and Other Dementias, August 1, 2006; 21(4): 258 - 262.
[Abstract] [PDF]


Home page
Int ImmunolHome page
M. Oroszlan, E. Herczenik, S. Rugonfalvi-Kiss, A. Roos, A. J Nauta, M. R Daha, I. Gombos, I. Karadi, L. Romics, Z. Prohaszka, et al.
Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP
Int. Immunol., June 1, 2006; 18(6): 871 - 878.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, I. Jialal, B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, and I. Jialal
The Verdict Is Still Out
Circulation, May 2, 2006; 113(17): 2128 - 2151.
[Full Text] [PDF]


Home page
Psychosom. Med.Home page
M. Hamer, E. Williams, R. Vuonovirta, P. Giacobazzi, E. L. Gibson, and A. Steptoe
The Effects of Effort-Reward Imbalance on Inflammatory and Cardiovascular Responses to Mental Stress
Psychosom Med, May 1, 2006; 68(3): 408 - 413.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Basu, S. Devaraj, and I. Jialal
Dietary Factors That Promote or Retard Inflammation
Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 995 - 1001.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
Circulation, April 18, 2006; 113(15): 1888 - 1904.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Jialal, S. Devaraj, and U. Singh
C-Reactive Protein and the Vascular Endothelium: Implications for Plaque Instability
J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1379 - 1381.
[Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
S. E Kasim-Karakas, A. Tsodikov, U. Singh, and I. Jialal
Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake.
Am. J. Clinical Nutrition, April 1, 2006; 83(4): 774 - 779.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Pauletto and M. Rattazzi
Inflammation and hypertension: the search for a link
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 850 - 853.
[Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev, April 1, 2006; 86(2): 515 - 581.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S.-R. Ji, Y. Wu, L. A. Potempa, Y.-H. Liang, and J. Zhao
Effect of Modified C-Reactive Protein on Complement Activation: A Possible Complement Regulatory Role of Modified or Monomeric C-Reactive Protein in Atherosclerotic Lesions
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 935 - 941.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Mineo and P. W. Shaul
Circulating cardiovascular disease risk factors and signaling in endothelial cell caveolae
Cardiovasc Res, April 1, 2006; 70(1): 31 - 41.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
I. Jialal and U. Singh
Is vitamin C an antiinflammatory agent?
Am. J. Clinical Nutrition, March 1, 2006; 83(3): 525 - 526.
[Full Text] [PDF]


Home page
DiabetesHome page
S. Devaraj, N. Glaser, S. Griffen, J. Wang-Polagruto, E. Miguelino, and I. Jialal
Increased Monocytic Activity and Biomarkers of Inflammation in Patients With Type 1 Diabetes
Diabetes, March 1, 2006; 55(3): 774 - 779.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Can, S. Acikgoz, G. Mungan, T. Bayraktaroglu, E. Kocak, B. Guven, and S. Demirtas
Serum cardiovascular risk factors in obstructive sleep apnea.
Chest, February 1, 2006; 129(2): 233 - 237.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Mineo, A. K. Gormley, I. S. Yuhanna, S. Osborne-Lawrence, L. L. Gibson, L. Hahner, R. V. Shohet, S. Black, J. E. Salmon, D. Samols, et al.
Fc{gamma}RIIB Mediates C-Reactive Protein Inhibition of Endothelial NO Synthase
Circ. Res., November 25, 2005; 97(11): 1124 - 1131.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
E. Fosslien
Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. G. Herman and S. Moncada
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. Torzewski
C-Reactive Protein and Atherogenesis: New Insights from Established Animal Models
Am. J. Pathol., October 1, 2005; 167(4): 923 - 925.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Pandolfi
C-reactive protein: A potential new molecular link between inflammation, thrombosis and vascular cell proliferation?
Cardiovasc Res, October 1, 2005; 68(1): 3 - 4.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Feinbloom and K. A. Bauer
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Nakakuki, M. Ito, H. Iwasaki, Y. Kureishi, R. Okamoto, N. Moriki, M. Kongo, S. Kato, N. Yamada, N. Isaka, et al.
Rho/Rho-Kinase Pathway Contributes to C-Reactive Protein-Induced Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2088 - 2093.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M Rattazzi, E Faggin, B Bertipaglia, and P Pauletto
Innate immunity and atherogenesis
Lupus, September 1, 2005; 14(9): 747 - 751.
[Abstract] [PDF]


Home page
GlycobiologyHome page
M. M. Chavan, P. D. Kawle, and N. G. Mehta
Increased sialylation and defucosylation of plasma proteins are early events in the acute phase response
Glycobiology, September 1, 2005; 15(9): 838 - 848.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. B. Schwedler, K. Amann, K. Wernicke, A. Krebs, M. Nauck, C. Wanner, L. A. Potempa, and J. Galle
Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E-Knockout Mice
Circulation, August 16, 2005; 112(7): 1016 - 1023.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and W. Koenig
Plasma Oxidized Low-Density Lipoprotein, a Strong Predictor for Acute Coronary Heart Disease Events in Apparently Healthy, Middle-Aged Men From the General Population
Circulation, August 2, 2005; 112(5): 651 - 657.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Devaraj, G. O'Keefe, and I. Jialal
Defining the Proinflammatory Phenotype Using High Sensitive C-Reactive Protein Levels as the Biomarker
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4549 - 4554.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Devaraj, T. W. Du Clos, and I. Jialal
Binding and Internalization of C-Reactive Protein by Fcgamma Receptors on Human Aortic Endothelial Cells Mediates Biological Effects
Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1359 - 1363.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. E. Taylor, J. C. Giddings, and C. W. van den Berg
C-Reactive Protein-Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide
Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1225 - 1230.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. K. Venugopal, S. Devaraj, and I. Jialal
Macrophage Conditioned Medium Induces the Expression of C-Reactive Protein in Human Aortic Endothelial Cells: Potential for Paracrine/Autocrine Effects
Am. J. Pathol., April 1, 2005; 166(4): 1265 - 1271.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
J. Lipid Res., March 1, 2005; 46(3): 389 - 403.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
A. Tedgui
The role of inflammation in atherothrombosis: implications for clinical practice
Vascular Medicine, February 1, 2005; 10(1): 45 - 53.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
M. V. Suresh, S. K. Singh, and A. Agrawal
Interaction of Calcium-bound C-reactive Protein with Fibronectin Is Controlled by pH: IN VIVO IMPLICATIONS
J. Biol. Chem., December 10, 2004; 279(50): 52552 - 52557.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Black, I. Kushner, and D. Samols
C-reactive Protein
J. Biol. Chem., November 19, 2004; 279(47): 48487 - 48490.
[Abstract] [Full Text] [PDF]